VRM
MRK icon

Vectors Research Management’s Merck MRK Stock Holding History

Vectors Research Management’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Sell
2,747
-45
-2% -$5.27K 0.09% 121
2026
Q1 		$336K Buy
2,792
+80
+3% +$9.24K 0.1% 117
2025
Q4 		$285K Sell
2,712
-33
-1% -$3.1K 0.09% 110
2025
Q3 		$230K Hold
2,745
– – 0.07% 124
2025
Q2 		$217K Sell
2,745
-11,694
-81% -$930K 0.07% 111
2025
Q1 		$1.3M Buy
14,439
+16
+0.1% +$1.49K 0.45% 62
2024
Q4 		$1.43M Sell
14,423
-1,535
-10% -$158K 0.49% 58
2024
Q3 		$1.81M Sell
15,958
-385
-2% -$45.7K 0.55% 53
2024
Q2 		$2.02M Sell
16,343
-499
-3% -$64.3K 0.62% 46
2024
Q1 		$2.22M Sell
16,842
-1,090
-6% -$134K 0.63% 43
2023
Q4 		$1.96M Sell
17,932
-315
-2% -$32.7K 0.55% 53
2023
Q3 		$1.75M Buy
18,247
+286
+2% +$30.8K 0.57% 51
2023
Q2 		$2.07M Sell
17,961
-1,036
-5% -$118K 0.59% 49
2023
Q1 		$2.02M Sell
18,997
-213
-1% -$23K 0.52% 49
2022
Q4 		$2.13M Buy
19,210
+982
+5% +$100K 0.55% 47
2022
Q3 		$1.57M Sell
18,228
-410
-2% -$36.6K 0.44% 57
2022
Q2 		$1.7M Sell
18,638
-415
-2% -$36.8K 0.43% 56
2022
Q1 		$1.56M Buy
19,053
+301
+2% +$23.7K 0.34% 69
2021
Q4 		$1.44M Buy
18,752
+828
+5% +$65.9K 0.3% 74
2021
Q3 		$1.35M Buy
17,924
+968
+6% +$73.6K 0.32% 69
2021
Q2 		$1.32M Sell
16,956
-367
-2% -$27.3K 0.34% 70
2021
Q1 		$1.27M Sell
17,323
-72
-0.4% -$5.31K 0.35% 66
2020
Q4 		$1.36M Buy
17,395
+7,133
+70% +$546K 0.42% 56
2020
Q3 		$815K Sell
10,262
-84
-0.8% -$6.58K 0.3% 73
2020
Q2 		$763K Buy
10,346
+7,333
+243% +$552K 0.3% 68
2020
Q1 		$221K Hold
3,013
– – 0.11% 101
2019
Q4 		$261K Sell
3,013
-9
-0.3% -$739 0.11% 101
2019
Q3 		$243K Sell
3,022
-26
-0.9% -$2.08K 0.12% 102
2019
Q2 		$244K Buy
3,048
+1
+0% +$77 0.13% 93
2019
Q1 		$242K Buy
3,047
+2,464
+423% +$184K 0.14% 95
2018
Q4 		$43K Sell
583
-2,121
-78% -$150K 0.02% 200
2018
Q3 		$156K Buy
+2,704
New +$172K 0.1% 119

Other funds holding MRK

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

Vectors Research Management's MRK Position: Q2 2026 in Review

Vectors Research Management reduced its Merck (MRK) stake by 1.6% in Q2 2026, selling an estimated $5.27K and leaving 2,747 shares worth $353K. The position accounts for 0.09% of the portfolio, ranked #121.

Vectors Research Management first reported a position in MRK in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.22M in Q1 2024. 1,660 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Vectors Research Management held 2,747 shares of Merck worth $353K as of Q2 2026.
  • Vectors Research Management sold 45 Merck shares in Q2 2026, an estimated $5.27K.
  • Merck made up 0.09% of Vectors Research Management's portfolio in Q2 2026, its #121 holding.
  • Vectors Research Management first reported a position in Merck in Q3 2018 and has held it in 32 quarters since.
  • Vectors Research Management's Merck position peaked at $2.22M in Q1 2024.
  • 1,660 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Vectors Research Management's 13F filing for Q2 2026, filed 29 Jul 2026.